Author:
Locke Frederick,Clark Joseph I.,Gajewski Thomas F.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference37 articles.
1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116
2. Johnson RO, Metter G, Wilson W, Hill G, Krementz E (1976) Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. Cancer Treat Rep 60:183–187
3. Patel PM (2008) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV malignant melanoma final results of the randomized phase III study (EORTC 18032). In: 33rd congress of the European Society for Medical Oncology
4. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR (2007) Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 33:665–680
5. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527–534
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献